World Investment Advisors Boosts Stake in Sanofi (NASDAQ:SNY)

World Investment Advisors raised its position in Sanofi (NASDAQ:SNY - Free Report) by 17.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,122 shares of the company's stock after buying an additional 8,578 shares during the quarter. World Investment Advisors' holdings in Sanofi were worth $3,279,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SNY. Cardinal Capital Management boosted its stake in shares of Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after purchasing an additional 199 shares in the last quarter. Gradient Investments LLC boosted its stake in shares of Sanofi by 2.1% in the 1st quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after purchasing an additional 200 shares in the last quarter. Providence Capital Advisors LLC boosted its stake in shares of Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after purchasing an additional 201 shares in the last quarter. Perigon Wealth Management LLC boosted its stake in shares of Sanofi by 3.1% in the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after purchasing an additional 201 shares in the last quarter. Finally, Beacon Financial Group boosted its stake in shares of Sanofi by 1.6% in the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after purchasing an additional 222 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Up 0.3%

SNY stock traded up $0.17 during midday trading on Tuesday, reaching $48.49. 265,218 shares of the company's stock traded hands, compared to its average volume of 2,601,276. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The company has a market cap of $118.91 billion, a price-to-earnings ratio of 17.32, a P/E/G ratio of 1.05 and a beta of 0.48. The firm's fifty day moving average price is $50.52 and its 200-day moving average price is $52.12. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm's quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.78 EPS. As a group, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were paid a $2.0369 dividend. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio (DPR) is 57.14%.

Analysts Set New Price Targets

Several research analysts have issued reports on SNY shares. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.